drugset / Trial / NCT06902740

Summary

This is a prospective, multicenter, open-label, blinded-endpoint, randomized controlled trial designed to evaluate the efficacy and safety of PCSK9 inhibitor combined with statin therapy compared to statin monotherapy in reversing asymptomatic intracranial atherosclerosis, assessed using high-resolution magnetic resonance imaging of the intracranial vessel walls.

Timeline

Start
2025-11-07
Primary completion
2027-12-31
Completion
2028-12-31

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Recaticimab Monoclonal antibody 450 mg Subcutaneous
Comparator Atorvastatin Small molecule 20 mg
Comparator Rosuvastatin Small molecule 10 mg